Market revenue in 2022 | USD 1,267.9 million |
Market revenue in 2030 | USD 2,114.1 million |
Growth rate | 6.6% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.96% in 2022. Horizon Databook has segmented the Germany hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
The large geriatric population in this region is a major driver of this market. According to UN population data, one in every 20 Germans is aged above 80, and the number is expected to increase to six by 2050. Problems faced due to increasing geriatric population include a high risk of thyroid diseases, menopause-associated issues, and hormonal diseases.
Supportive government policies, high investments in improving healthcare infrastructure, and various initiatives undertaken by public & private organizations to increase disease awareness are expected to boost the market in Germany.
According to World Bank, in 2020, the number of women aged 65 and above was around 10.1 million in Germany. Women in this age group are prone to postmenopausal problems, such as osteoporosis. All these factors are likely to drive the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Germany hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account